HRP20140486T1 - Postupci sinteze spojeva spirooksindola - Google Patents
Postupci sinteze spojeva spirooksindola Download PDFInfo
- Publication number
- HRP20140486T1 HRP20140486T1 HRP20140486AT HRP20140486T HRP20140486T1 HR P20140486 T1 HRP20140486 T1 HR P20140486T1 HR P20140486A T HRP20140486A T HR P20140486AT HR P20140486 T HRP20140486 T HR P20140486T HR P20140486 T1 HRP20140486 T1 HR P20140486T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- image
- obtaining
- Prior art date
Links
- 238000010189 synthetic method Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 40
- 150000003839 salts Chemical class 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 14
- 238000006243 chemical reaction Methods 0.000 claims 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 239000007818 Grignard reagent Substances 0.000 claims 2
- 238000006751 Mitsunobu reaction Methods 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 150000004795 grignard reagents Chemical class 0.000 claims 2
- 239000013067 intermediate product Substances 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Furan Compounds (AREA)
Claims (8)
1. Postupak dobivanja spoja formule (I):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
naznačen time što se postupak sastoji u:
a) obradi spoja formule (7):
[image]
,
ili njegove farmaceutski prihvatljive soli, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli; i
b) obradi spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, spojem formule (9):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I),
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
2. Postupak u skladu s patentnim zahtjevom 1, koji se dodatno sastoji u dobivanju spoja formule (7), naznačen time što se postupak sastoji u obradi spoja formule (6):
[image]
,
ili njegove farmaceutski prihvatljive soli, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7),
ili njegovu farmaceutski prihvatljivu sol.
3. Postupak u skladu s patentnim zahtjevom 2, koji se dodatno sastoji u dobivanju spoja formule (6), naznačen time što se postupak sastoji u obradi spoja formule (5):
[image]
,
ili njegove farmaceutski prihvatljive sol, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6),
ili njegove farmaceutski prihvatljive soli.
4. Postupak u skladu s patentnim zahtjevom 3, koji se dodatno sastoji u dobivanju spoja formule (5), naznačen time što se postupak sastoji u obradi spoja formule (4):
[image]
,
ili njegove farmaceutski prihvatljive soli, u uvjetima pogodnim za dobivanje spoja formule (5),
ili njegove farmaceutski prihvatljive soli.
5. Postupak u skladu s patentnim zahtjevom 4, koji se dodatno sastoji u dobivanju spoja formule (4), naznačen time što se postupak sastoji u:
a) reakciji spoja formule (2):
[image]
,
ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3):
[image]
u uvjetima pogodnim za dobivanje međuprodukta; i
b) reakciji međuprodukta iz a) sa spojem formule (1):
[image]
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4),
ili njegove farmaceutski prihvatljive soli.
6. Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S):
[image]
,
ili njegove farmaceutski prihvatljive sol, i spoja formule (I-R):
[image]
,
ili njegove farmaceutski prihvatljive soli.
7. Postupak dobivanja spoja formule (I):
[image]
,
ili njegove farmaceutski prihvatljive sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, naznačen time što se postupak sastoji u:
a) reakciji spoja formule (2):
[image]
,
ili njegove farmaceutski prihvatljive soli, s Grignardovim reagensom formule (3):
[image]
u uvjetima pogodnim za dobivanje međuprodukta; i
b) reakciji međuprodukta iz a) sa spojem formule (1):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (4):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
c) obradi spoja formule (4), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, u uvjetima pogodnim za dobivanje spoja formule (5):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
d) obradi spoja formule (5), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, aldehidom u uvjetima pogodnim za dobivanje spoja formule (6):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
e) obradi spoja formule (6), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, u standardnim uvjetima za Mitsunobuovu reakciju, kako bi se dobilo spoj formule (7):
[image]
,
ili njegovu farmaceutski prihvatljivu sol, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
f) obradi spoja formule (7), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, bazom u uvjetima pogodnim za dobivanje spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese;
g) obradi spoja formule (8):
[image]
,
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese, spojem formule (9):
[image]
,
ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I),
ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
8. Postupak u skladu s patentnim zahjevom 7, naznačen time što se dodatno sastoji u razdvajanju spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-S):
[image]
,
ili njegove farmaceutski prihvatljive soli, i spoja formule (I-R):
[image]
,
ili njegove farmaceutski prihvatljive soli.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25133509P | 2009-10-14 | 2009-10-14 | |
PCT/US2010/052704 WO2011047174A1 (en) | 2009-10-14 | 2010-10-14 | Synthetic methods for spiro-oxindole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140486T1 true HRP20140486T1 (hr) | 2014-07-04 |
Family
ID=43733239
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120368AA HRP20120368A2 (hr) | 2009-10-14 | 2012-04-27 | Postupci sinteze spiro-oksindolskih spojeva |
HRP20140486AT HRP20140486T1 (hr) | 2009-10-14 | 2014-05-29 | Postupci sinteze spojeva spirooksindola |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20120368AA HRP20120368A2 (hr) | 2009-10-14 | 2012-04-27 | Postupci sinteze spiro-oksindolskih spojeva |
Country Status (23)
Country | Link |
---|---|
US (4) | US8445696B2 (hr) |
EP (2) | EP2488531B1 (hr) |
JP (3) | JP5752136B2 (hr) |
KR (1) | KR20120099429A (hr) |
CN (1) | CN102753556B (hr) |
AU (2) | AU2010306768B2 (hr) |
BR (1) | BR112012008993A2 (hr) |
CA (1) | CA2777543A1 (hr) |
CL (3) | CL2012000953A1 (hr) |
CO (1) | CO6531444A2 (hr) |
EC (1) | ECSP12011815A (hr) |
ES (1) | ES2467166T3 (hr) |
HK (2) | HK1174908A1 (hr) |
HR (2) | HRP20120368A2 (hr) |
MA (1) | MA33730B1 (hr) |
MX (1) | MX2012004373A (hr) |
MY (2) | MY179342A (hr) |
NZ (3) | NZ599334A (hr) |
PE (2) | PE20170202A1 (hr) |
RU (2) | RU2544852C2 (hr) |
TN (1) | TN2012000171A1 (hr) |
WO (1) | WO2011047174A1 (hr) |
ZA (1) | ZA201202703B (hr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
CA2665698A1 (en) | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8263606B2 (en) * | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
MY165117A (en) | 2010-02-26 | 2018-02-28 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
KR20150002794A (ko) * | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
CN103724340A (zh) * | 2012-10-15 | 2014-04-16 | 南京大学 | 一类具有苯并含氧杂环结构的噻唑类衍生物及其制法 |
CN104326922B (zh) * | 2014-11-03 | 2016-08-17 | 成都百裕制药股份有限公司 | 替格瑞洛中间体(1r,2s)-2-(2,3-二氟苯基)环丙胺的制备方法 |
CN105801556A (zh) * | 2014-12-31 | 2016-07-27 | 上海药谷药业有限公司 | 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法 |
WO2016109795A1 (en) | 2014-12-31 | 2016-07-07 | Concert Pharmaceuticals, Inc. | Deuterated funapide and difluorofunapide |
WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
PE20181495A1 (es) | 2015-12-18 | 2018-09-18 | Merck Sharp & Dohme | Compuestos de diamina-arilsulfonamida sustituidos con hidroxialquilamina e hidroxicicloalquilamina con actividad selectiva en canales de sodio activados por voltaje |
US10100060B2 (en) | 2016-06-16 | 2018-10-16 | Xenon Pharmaceuticals Inc. | Asymmetric synthesis of funapide |
JP2019518058A (ja) * | 2016-06-16 | 2019-06-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | スピロ−オキシインドール化合物の固体状態形 |
US11306100B2 (en) | 2017-03-10 | 2022-04-19 | Council Of Scientific & Industrial Research | Spirooxindole compounds as GSK3B inhibitors and process for preparation thereof |
JP2024500286A (ja) | 2020-11-23 | 2024-01-09 | エナンタ ファーマシューティカルズ インコーポレイテッド | 新規スピロピロリジン誘導抗ウイルス剤 |
WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
US11912714B2 (en) | 2021-11-12 | 2024-02-27 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
WO2023086400A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
WO2023107419A1 (en) | 2021-12-08 | 2023-06-15 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
US20230295175A1 (en) * | 2022-03-18 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of substituted spirooxindole derivatives |
CN115353499B (zh) * | 2022-10-21 | 2023-02-28 | 南京远淑医药科技有限公司 | 一种2-卤甲基-5-三氟甲基呋喃的合成方法 |
US11840545B1 (en) | 2023-07-14 | 2023-12-12 | King Faisal University | Spirooxindole-copper complex as novel efficient anticorrosion agent for C-steel |
Family Cites Families (151)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3189617A (en) | 1961-02-03 | 1965-06-15 | Sterling Drug Inc | 1-aryloxindoles and their preparation |
DE1956237A1 (de) | 1969-11-08 | 1971-05-13 | Basf Ag | Spiro-pyrrolizidon-oxindole |
DE2113343A1 (de) | 1971-03-19 | 1972-09-21 | Thiemann Chem Pharm Fab | Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung |
US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
CH577461A5 (hr) | 1975-08-13 | 1976-07-15 | Robins Co Inc A H | |
US4670566A (en) | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4440785A (en) | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
US4438130A (en) | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
JPS60142984A (ja) | 1983-12-28 | 1985-07-29 | Kyorin Pharmaceut Co Ltd | 新規なスピロピロリジン−2,5−ジオン誘導体およびその製造法 |
US4569942A (en) | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
JPS6130554A (ja) | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
US4690943A (en) | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
DE3608088C2 (de) | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
JP2716986B2 (ja) | 1987-07-17 | 1998-02-18 | シエーリング アクチエンゲゼルシヤフト | 9‐ハロゲン‐(z)‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用 |
US5182289A (en) | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
KR930011300B1 (ko) | 1989-07-25 | 1993-11-29 | 다이호오 야꾸힌 고오교오 가부시끼가이샤 | 옥시인돌유도체 |
DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5023265A (en) | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
US5484778C1 (en) | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
WO1992009577A1 (en) | 1990-11-22 | 1992-06-11 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
US5116854A (en) | 1991-06-28 | 1992-05-26 | Pfizer Inc. | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles |
US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
CZ283965B6 (cs) | 1992-08-06 | 1998-07-15 | Warner-Lambert Company | 2-thioindolové, 2-indolinthionové a polysulfidové sloučeniny, 2-selenoindolové, 2-indolinselenonové a selenidové sloučeniny a farmaceutické prostředky na jejich bázi |
US5278162A (en) | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
US5296478A (en) | 1992-10-07 | 1994-03-22 | The Dupont Merck Pharmaceutical Co. | 1-substituted oxindoles as cognition enhancers |
US5776936A (en) | 1992-11-13 | 1998-07-07 | Pharmacia & Upjohn Company | Marcfortine/paraherquamide derivatives useful as antiparasitic agents |
DE4242451A1 (de) | 1992-12-16 | 1994-06-23 | Basf Ag | Verfahren zur Herstellung von 5-Ringheterocyclen |
US5298522A (en) | 1993-01-22 | 1994-03-29 | Pfizer Inc. | 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio |
US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
AT400950B (de) | 1994-02-04 | 1996-04-25 | Immodal Pharmaka Gmbh | Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen |
WO1995027712A1 (fr) | 1994-04-07 | 1995-10-19 | Cemaf | Nouveaux derives de spiro[indole-pyrrolidine] agonistes melatoninergiques, leur procede de preparation et leur utilisation a titre de medicament |
US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
FR2722195B1 (fr) | 1994-07-07 | 1996-08-23 | Adir | Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CZ192397A3 (en) | 1994-12-22 | 1997-09-17 | Smithkline Beecham Plc | Tetracyclic spiro-compounds, process of their preparation and use as 5ht1d receptors |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
CA2235686C (en) | 1995-10-24 | 2007-06-26 | Sanofi | Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
HUP9600855A3 (en) | 1996-04-03 | 1998-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tenidap |
JPH1095766A (ja) | 1996-09-19 | 1998-04-14 | Sanwa Kagaku Kenkyusho Co Ltd | アセトアミド誘導体、及びその用途 |
FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
DE59814452D1 (de) | 1997-01-20 | 2010-06-24 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
EP1008588B1 (en) | 1997-02-10 | 2003-04-16 | Ono Pharmaceutical Co., Ltd. | 11,15-o-dialkylprostaglandin e derivatives, process for producing the same, and drugs containing the same as the active ingredient |
EP0981327B1 (en) | 1997-05-07 | 2002-11-06 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
ES2216336T3 (es) | 1997-12-25 | 2004-10-16 | Ono Pharmaceutical Co., Ltd. | Derivados omega-cicloalquilos de la prostaglandina e2. |
JP4087938B2 (ja) | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
CN1217918C (zh) | 1998-04-01 | 2005-09-07 | 卡迪欧梅制药公司 | 氨基环己基醚化合物和其用途 |
US20040038970A1 (en) | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
AU5227999A (en) | 1998-07-27 | 2000-02-21 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
TR200103352T2 (tr) | 1999-05-21 | 2005-03-21 | Bristol-Myers Squibb Company | Kinas pirolotriazin inhibitörleri |
JP3833532B2 (ja) | 1999-07-21 | 2006-10-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性疾患の治療において有用な小分子 |
RU2002104496A (ru) | 1999-07-21 | 2003-09-27 | Астразенека Аб (Se) | Новые соединения |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
EP1252330A2 (en) | 1999-11-26 | 2002-10-30 | McGill University | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
US20020045566A1 (en) | 2000-10-13 | 2002-04-18 | Gribkoff Valentin K. | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
US6825220B2 (en) | 2000-11-10 | 2004-11-30 | Eli Lilly And Company | 3-Substituted oxindole β 3 agonists |
US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
US20030078278A1 (en) | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
EP1444224B1 (en) | 2001-08-14 | 2006-05-03 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
CA2465207C (en) | 2001-11-01 | 2011-01-04 | Icagen, Inc. | Pyrazole-amides and -sulfonamides |
US7244744B2 (en) | 2001-11-01 | 2007-07-17 | Icagen, Inc. | Piperidines |
WO2003044016A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
JP2005519921A (ja) | 2002-01-28 | 2005-07-07 | ファイザー株式会社 | Orl−1受容体リガンドとしてのn置換スピロピペリジン化合物 |
US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
US7250442B2 (en) | 2002-03-15 | 2007-07-31 | Eli Lilly And Company | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators |
US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
IL165395A0 (en) | 2002-06-25 | 2006-01-15 | Wyeth Corp | Use of thio-oxubdile derivatives in treatment of hormone-related conditions |
BR0312092A (pt) | 2002-06-25 | 2005-03-22 | Wyeth Corp | Uso de derivados de tio-oxindol no tratamento de distúrbios da pele |
US7256218B2 (en) | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
KR20120102571A (ko) | 2003-02-24 | 2012-09-18 | 미쓰비시 타나베 파마 코퍼레이션 | 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도 |
MXPA05012391A (es) | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamiento de trastornos psicoticos y depresivos. |
CA2525868A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Anxiety treatments with ziprasidone |
KR20060009938A (ko) | 2003-05-16 | 2006-02-01 | 화이자 프로덕츠 인코포레이티드 | 양극성 장애 및 연관된 증상의 치료 |
MXPA05012325A (es) | 2003-05-16 | 2006-01-30 | Pfizer Prod Inc | Procedimiento para potenciar la cognicion usando zipirasidona. |
JP4838128B2 (ja) | 2003-07-30 | 2011-12-14 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピペラジン誘導体および治療剤としてのその用途 |
DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
JPWO2005035498A1 (ja) | 2003-10-08 | 2006-12-21 | 住友製薬株式会社 | 含窒素二環性化合物の摂食調節剤としての用途 |
EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
GB0406867D0 (en) | 2004-03-26 | 2004-04-28 | F2G Ltd | Antifungal agents |
CA2560796A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
BRPI0509307A (pt) | 2004-03-29 | 2007-09-04 | Pfizer | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 |
GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
US8211883B2 (en) | 2004-04-01 | 2012-07-03 | Case Western Reserve University | Topical delivery of phthalocyanines |
US20070299102A1 (en) | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
CN1953967B (zh) | 2004-04-27 | 2013-03-13 | 惠氏公司 | 孕酮受体调节剂的纯化 |
ZA200607620B (en) * | 2004-05-05 | 2008-05-28 | Unibioscreen Sa | Naphthalimide derivatives, methods for their production and pharmaceutical composition therefrom |
JP2007536283A (ja) * | 2004-05-05 | 2007-12-13 | ユニバイオスクリーン エス.アー. | ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物 |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
AU2005267331A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
JP4677323B2 (ja) | 2004-11-01 | 2011-04-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
BRPI0518281A2 (pt) | 2004-11-18 | 2008-11-18 | Incyte Corp | inibidores de 11-beta hidroxilesteràide desidrogenase do tipo i e mÉtodos uso dos mesmos |
DE102005007694A1 (de) | 2005-02-18 | 2006-09-21 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
CA2752738C (en) | 2005-02-22 | 2014-05-27 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
BRPI0608221A2 (pt) | 2005-04-29 | 2009-11-24 | Wyeth Corp | métodos para preparação de um composto, e para preparar seletivamente um composto de nitrila, e, composto |
TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
MX2008002733A (es) * | 2005-09-01 | 2008-03-26 | Hoffmann La Roche | Diaminopirimidinas como moduladores p2x3 y p2x2/3. |
EP2032539A4 (en) | 2006-06-09 | 2011-03-16 | Merck Sharp & Dohme | BENZAZEPINONES AS BLOCKERS OF SODIUM CHANNELS |
WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
WO2008046084A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
WO2008046087A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
CL2007002951A1 (es) | 2006-10-12 | 2008-02-01 | Xenon Pharmaceuticals Inc | Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer. |
AU2007307635A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
AU2007307638A1 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
CA2665698A1 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
EP3357904B1 (en) | 2007-05-29 | 2022-07-06 | Precigen, Inc. | Chiral diachylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
CA2920996A1 (en) * | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP2288603A1 (en) * | 2008-06-11 | 2011-03-02 | Actelion Pharmaceuticals Ltd. | Tetrazole compounds as orexin receptor antagonists |
US20100040187A1 (en) | 2008-08-12 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Heat pipe nuclear fission deflagration wave reactor cooling |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2010053998A1 (en) | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
US20110269788A1 (en) | 2008-12-29 | 2011-11-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
WO2010132352A2 (en) | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
US20110086899A1 (en) | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
MY165117A (en) | 2010-02-26 | 2018-02-28 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
KR20150002794A (ko) | 2012-04-12 | 2015-01-07 | 제논 파마슈티칼스 인크. | 치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성 |
-
2010
- 2010-10-14 RU RU2012119550/04A patent/RU2544852C2/ru not_active IP Right Cessation
- 2010-10-14 NZ NZ599334A patent/NZ599334A/en not_active IP Right Cessation
- 2010-10-14 MY MYPI2016001835A patent/MY179342A/en unknown
- 2010-10-14 EP EP10771606.0A patent/EP2488531B1/en active Active
- 2010-10-14 NZ NZ712378A patent/NZ712378A/en not_active IP Right Cessation
- 2010-10-14 AU AU2010306768A patent/AU2010306768B2/en not_active Ceased
- 2010-10-14 MY MYPI2012001670A patent/MY165579A/en unknown
- 2010-10-14 RU RU2015103694/04A patent/RU2015103694A/ru not_active Application Discontinuation
- 2010-10-14 EP EP14000519.0A patent/EP2733145A1/en not_active Withdrawn
- 2010-10-14 CN CN201080056856.0A patent/CN102753556B/zh not_active Expired - Fee Related
- 2010-10-14 NZ NZ622072A patent/NZ622072A/en not_active IP Right Cessation
- 2010-10-14 WO PCT/US2010/052704 patent/WO2011047174A1/en active Application Filing
- 2010-10-14 PE PE2016001459A patent/PE20170202A1/es not_active Application Discontinuation
- 2010-10-14 JP JP2012534362A patent/JP5752136B2/ja not_active Expired - Fee Related
- 2010-10-14 BR BR112012008993A patent/BR112012008993A2/pt not_active Application Discontinuation
- 2010-10-14 CA CA2777543A patent/CA2777543A1/en not_active Abandoned
- 2010-10-14 MX MX2012004373A patent/MX2012004373A/es active IP Right Grant
- 2010-10-14 US US12/904,880 patent/US8445696B2/en active Active
- 2010-10-14 ES ES10771606.0T patent/ES2467166T3/es active Active
- 2010-10-14 PE PE2012000480A patent/PE20121350A1/es not_active Application Discontinuation
- 2010-10-14 KR KR1020127012050A patent/KR20120099429A/ko not_active Application Discontinuation
-
2012
- 2012-04-13 CO CO12061009A patent/CO6531444A2/es unknown
- 2012-04-13 TN TNP2012000171A patent/TN2012000171A1/en unknown
- 2012-04-13 ZA ZA2012/02703A patent/ZA201202703B/en unknown
- 2012-04-13 CL CL2012000953A patent/CL2012000953A1/es unknown
- 2012-04-18 EC ECSP12011815 patent/ECSP12011815A/es unknown
- 2012-04-27 HR HRP20120368AA patent/HRP20120368A2/hr not_active Application Discontinuation
- 2012-05-07 MA MA34841A patent/MA33730B1/fr unknown
- 2012-09-14 US US13/620,391 patent/US8742109B2/en not_active Expired - Fee Related
-
2013
- 2013-02-15 HK HK13101970.7A patent/HK1174908A1/xx not_active IP Right Cessation
- 2013-12-18 CL CL2013003633A patent/CL2013003633A1/es unknown
-
2014
- 2014-05-07 US US14/272,297 patent/US9260446B2/en not_active Expired - Fee Related
- 2014-05-29 HR HRP20140486AT patent/HRP20140486T1/hr unknown
- 2014-10-22 HK HK14110536A patent/HK1197233A1/xx unknown
-
2015
- 2015-03-02 JP JP2015039888A patent/JP5951825B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-06 US US14/989,600 patent/US9695185B2/en not_active Expired - Fee Related
- 2016-04-15 JP JP2016081755A patent/JP2016130260A/ja active Pending
- 2016-07-06 CL CL2016001732A patent/CL2016001732A1/es unknown
- 2016-07-27 AU AU2016208347A patent/AU2016208347A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140486T1 (hr) | Postupci sinteze spojeva spirooksindola | |
JP2010043124A5 (hr) | ||
FR2998297B1 (fr) | Procede de preparation de sel d'imides contenant un groupement fluorosulfonyle | |
WO2015145415A3 (en) | Ibrutinib solid forms and production process therefor | |
FR2956867B1 (fr) | Procede de preparation d'un echantillon d'hemoculture contenant des microorganismes | |
FR2982610B1 (fr) | Procede de preparation de sel d'anion pentacylique | |
IL275585B1 (en) | A process for separating enantiomers of nicotine from a serial mixture | |
EP2750789A4 (en) | SPOX OXIDIZATION PROCESS FOR PREPARING 2,5-FURANDIC ACETIC ACID FROM HYDROXYMETHYL FURFURAL | |
EP2484673A3 (en) | A process for the resolution of (R,S)-nicotine | |
MA40544B1 (fr) | Procédé de production d'un carbonate lié, article moulé sous pression | |
MX336925B (es) | Procedimiento para elaborar acido lactico. | |
EP3075732A3 (en) | Process for the preparation of (r)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane and process for the preparation of the intermediate 5-chloro-2-(4-methylphenyl)pyridine | |
WO2016077832A3 (en) | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | |
HRP20200437T1 (hr) | Proces za pripremu enantiomerom obogaćenog 3-aminopiperidina | |
FR2934160B1 (fr) | Procede de preparation d'un extrait lipophile de vigne. | |
WO2012093411A3 (en) | Process for the preparation of r-(-)-3- (carbamoylmethyl)-5-methylhexanoic acid and the intermediates | |
WO2009065872A3 (en) | Processes for the synthesis of varenicline l-tartrate | |
FR3033702B1 (fr) | Procede de preparation d'un extrait de plante avec un compose amphiphile non ionique comme adjuvant d'extraction en milieu aqueux | |
FR3053336B1 (fr) | Procede de preparation de l'acide 2,5-furane dicarboxylique (fdca) a partir de derives de pentoses | |
FR2957076B1 (fr) | Procede de production d'acide pyrrolidonecarboxylique ou d'un sel de celui-ci, acide pyrrolidonecarboxylique ainsi obtenu et cosmetique le contenant | |
FR2947933B1 (fr) | Procede de traitement de donnees permettant le filtrage d'artefacts, adapte notamment a l'electroencephalographie | |
DE602007010926D1 (de) | Neues verfahren zur herstellung von ammoniumsalzen von esomeprazol | |
WO2012070896A3 (en) | Synthetic method of enantiomerically pure 2,2'-dihydroxy-1,1'-binaphthyl-3-carboxylic acid | |
IL214929A0 (en) | Process for producing 3-(2-cyano-1-propenyl)-2,2-dimethylcyclopropanecarboxylic acid or salt thereof | |
FR2935975B1 (fr) | Procede de preparation du 1,6:2,3-dianhydro-b-d- mannopyranose. |